
Molecular Weight: | 572.74 |
Formula: | C34H44N4O4 |
Purity: | ≥98% |
CAS#: | 1403254-99-8 |
Solubility: | DMSO up to 100 mM |
Chemical Name: | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide |
Storage: | Powder:4oC 1 year. DMSO:4oC3 month;-20oC 1 year. |
Biological Activity:
EPZ-6438 (E7438) is a potent and selective small molecule inhibitor of histone methyltransferase EZH2. It inhibited the activity of human PRC2-containing wild-type EZH2 with an inhibition constant (Ki) value of 2.5 ± 0.5 nM, and similar potency was observed for EZH2 proteins bearing all known lymphoma change-of-function mutations. EPZ-6438 inhibits EZH2 in a manner competitive with the substrate S-adenosylmethionine (SAM). EPZ-6438 displayed a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs (encompassing both lysine and arginine HMTs) tested. It specifically inhibits cellular H3K27 methylation leading to selective apoptotic killing of SMARCB1 mutant MRT Cells. It also induced genes of neuronal differentiation and cell cycle inhibition while suppressing expression of Hedgehog pathway genes, MYC and EZH2. Moreover EPZ-6438 leads to complete and sustained regression of SMARCB1 mutant MRT xenografts, and sevral EZH2 mutant xenografts including WSU-DLCL2 (Y614F), Pfeiffer (Y677G), KARPAS-422 (Y641N) etc. Epizyme has initiated a Phase 1/2 clinical trials targeting the treatment of non-Hodgkin lymphoma.
How to Use:
- In vitro: EPZ-6438 was used at 1 µM final concentration in vitro and in cellular assays.
- In vivo:EPZ-6438 was orally dosed to mice at 250-500 mg/kg twice per day for 21-28 days, leaded to complete and sustained regression of SMARCB1 mutant MRT xenografts (SCID mice bearing s.c. G401 xenograft).
Reference:
- 1. Knutson SK, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. (2013) Proc Natl Acad Sci U S A. 110(19):7922-7.
- 2. Robert A Copeland. Protein methyltransferases in cancer. (2013) AACR Annual Meeting.
EPZ-6438_spec.pdf
EPZ-6438_MSDS.pdf
Products are for research use only. Not for human use.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
天然产物,大多都有颜色,
存在干扰,多数情况下需要做样品的阴性对照,
尽量能用荧光的方法,
之前我们做过,将两个试剂盒的方法合并后,做的,
效果还可以
2.微孔板:选择实验所需的板条数。剩余不用的部分随同干燥剂密封放回原袋。 1.包被有抗抑制素bB亚单位抗体的微孔板(Anti-InhibinB-CoatedMicrotitrationStrips):96孔,2-8ºC下密封保存。
2.标准品A/样本稀释液(InhibinBStandardA/SampleDiluent):2ml×1瓶,胎牛血清,含0pg/mL二聚体抑制素B。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
3.标准品B-G(InhibinBStandardsB-G):1ml×6瓶,胎牛血清,含二聚体抑制素B的浓度为10,30,100,250,500,1000pg/mL。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
4.质控(InhibinBControls):1ml×2瓶,浓度I、II,胎牛血清,含低浓度和高浓度的抑制素A二聚体。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
5.样本稀释液A(InhibinBSampleBufferA):10ml×1瓶,2-8ºC下保存。
6.样本稀释液B(InhibinBSampleBufferB):10ml×1瓶,2-8ºC下保存。
7.抗体-生物素结合物(InhibinBAntibody-BiotinConjugate)(即用型):10ml×1瓶,含生物素标记的抗抑制素a亚单位抗体。2-8ºC下保存。
8.酶结合物(浓缩)(Streptavidin-EnzymeConjugate)(即用型):10ml×1瓶,含链霉和素-辣根过氧化物酶结合物。2-8ºC下保存。
9.TMB底物溶液(TMBChromogenSolution):15ml×1瓶,2-8ºC下保存。
10.终止液(StoppingSolution):15ml×1瓶,为0.2M的硫酸。2-8ºC下保存。
11.浓缩洗液(WashConcentrate):100ml×1瓶,2-8ºC下保存。 操作前所有试剂都应平衡至室温(~25ºC)并充分混匀。标准品、质控及待测样本需同时做双份。
1.取出实验所需板条,并记录各孔位置。
2.在对应的孔中加入标准品、质控及待测样本各50ul。
3.每孔加入25ul样本稀释液A。
4.每孔加入25ul样本稀释液B。
5.封板,以300-400rpm速度震荡,室温下过夜(14-18小时)。
6.洗板3次,在吸水纸上拍干。
7.每孔加入50ul抗体-生物素结合物。
8.封板,以500-700rpm速度震荡,室温下孵育1.5小时。
9.洗板6次,在吸水纸上拍干。
10.每孔加入50ul链霉和素-辣根过氧化物酶结合物。
11.封板,以500-700rpm速度震荡,室温下孵育20分钟。
12.洗板6次,洗完最后一次以后,将洗液在孔内停留15分钟再除去。在吸水纸上拍干。
13.在每孔中加入100ulTMB底物溶液。
14.以500-700rpm速度震荡,室温下避光孵育15-30分钟。
15.每孔加入100ul终止液。
16.30分钟内在450nm处读数。
注:必须以零标准作空白。如果能做到双波长测定,可在600或620nm处读数,将600(620)nm吸收值从450nm处减去,这样可以减少光学误差。 使用血清样本,静脉穿刺术采集血液。样本于2-8ºC可保存24小时,-20ºC或以下可保存30天。避免反复冻融样本。不应采用溶血或脂血的样本。冰冻的样本在实验前应解冻,并充分混匀。向左转|向右转
RMgX + RX = R-R + MgX2.
这个反应需要的能量比生成格氏试剂的高,
因此降低反应温度是第一个选择。
其次, 增加镁得摩尔比, 让 RX与镁有更多机会反应, 而不是与RMgX。
第三, 降低RX的浓度, 即用更多的溶剂, 因为溶剂和格氏试剂有很显著的溶剂络合。
第四, 缓慢滴加RX., 即降低RX.在反应体系的浓度。
第五, 增加搅拌速率, 即, 让RX.与镁有更好的接触。

